Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer

Breast Journal

Volumn 15, Issue 4, 2009, Pages 333-338

  Tiezzi, Daniel Guimarães ^a,b   De Andrade, Jurandyr Moreira ^a   Marana, Heitor Ricardo Cosiski ^a   Garieri, Alexandre Pavan ^a   De Paula Philbert, Paulo Meyer ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Breast cancer; Cancer in the elderly; Predictive factor; Primary hormone therapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; AGING; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; GERIATRIC PATIENT; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MENOPAUSE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; POSTMENOPAUSE; PREDICTION; PREOPERATIVE TREATMENT; PROGNOSIS; TREATMENT OUTCOME; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 67650742130     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00736.x     Document Type: Article

References (27)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 16 : 2672 85.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006 24 : 1940 9.
3. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997 15 : 2483 93.
4. Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003 86 : 295 9.
5. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002 38 : 2214 21.
6. Macaskill EJ, Renshaw L, Dixon JM. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 2006 11 : 1081 8.
7. Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev 2007 33 : 48 57. (Pubitemid 46132006)
8. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 1991 78 : 591 4.
9. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994 20 : 207 14.
10. Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The GRETA Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 1994 14 : 2197 200.
11. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992 28A : 908 10.
12. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 12 : 1527 32.
13. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001 19 : 3808 16.
14. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized Trial. J Clin Oncol 2005 23 : 5108 16.
15. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) Trial. Cancer 2006 106 : 2095 103.
16. Peiro G, Adrover E, Aranda FI, Peiro FM, Niveiro M, Sanchez-Paya J. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma. Am J Clin Pathol 2007 127 : 780 6.
17. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005 12 (Suppl 1 S47 59.
18. Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J 2006 12 (Suppl 1 S3 15.
19. Shyyan R, Masood S, Badwe RA, et al. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J 2006 12 (Suppl 1 S27 37.
20. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977 35 : 292 8.
21. Nicholson RI, Hutcheson IR, Hiscox SE, et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 2005 12 (Suppl 1 S29 36.
22. Allan SG, Rodger A, Smyth JF, Leonard RC, Chetty U, Forrest AP. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clinical Research Ed) 1985 290 : 358.
23. Bradbeer JW, Kyngdon J. Primary treatment of breast cancer in elderly women with Tamoxifen. Clin Oncol 1983 9 : 31 4.
24. Helleberg A, Lundgren B, Norin T, Sander S. Treatment of early localized breast cancer in elderly patients by Tamoxifen. Br J Radiol 1982 55 : 511 5.
25. Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clinical Research Ed) 1982 284 : 869 70.
26. Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005 94 : 255 63.
27. Akashi-Tanaka S, Omatsu M, Shimizu C, et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast 2007 16 : 482 8.